Reactive oxygen species are involved in FasL-induced caspase-independent cell death and inflammatory responses
Tài liệu tham khảo
Gerschenson, 1992, Apoptosis: a different type of cell death, FASEB J., 6, 2450, 10.1096/fasebj.6.7.1563596
Edinger, 2004, Death by design: apoptosis, necrosis and autophagy, Curr. Opin. Cell Biol., 16, 663, 10.1016/j.ceb.2004.09.011
Bursch, 2001, The autophagosomal–lysosomal compartment in programmed cell death, Cell Death Differ., 8, 569, 10.1038/sj.cdd.4400852
Tsujimoto, 2005, Another way to die: autophagic programmed cell death, Cell Death Differ., 12, 1528, 10.1038/sj.cdd.4401777
Longthorne, 1997, Caspase activity is required for commitment to Fas-mediated apoptosis, EMBO J., 16, 3805, 10.1093/emboj/16.13.3805
Barnhart, 2003, The CD95 type I/type II model, Semin. Immunol., 15, 185, 10.1016/S1044-5323(03)00031-9
Kroemer, 2005, Caspase-independent cell death, Nat. Med., 11, 725, 10.1038/nm1263
Chipuk, 2005, Do inducers of apoptosis trigger caspase-independent cell death?, Nat. Rev. Mol. Cell Biol., 6, 268, 10.1038/nrm1573
Vercammen, 1998, Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor, J. Exp. Med., 187, 1477, 10.1084/jem.187.9.1477
Khwaja, 1999, Resistance to the cytotoxic effects of tumor necrosis factor alpha can be overcome by inhibition of a FADD/caspase-dependent signaling pathway, J. Biol. Chem., 274, 36817, 10.1074/jbc.274.51.36817
Liu, 2003, Broad-spectrum caspase inhibition paradoxically augments cell death in TNF-alpha-stimulated neutrophils, Blood, 101, 295, 10.1182/blood-2001-12-0266
Lin, 2004, Tumor necrosis factor-induced nonapoptotic cell death requires receptor-interacting protein-mediated cellular reactive oxygen species accumulation, J. Biol. Chem., 279, 10822, 10.1074/jbc.M313141200
Huang, 2005, The augmentation of TNFalpha-induced cell death in murine L929 fibrosarcoma by the pan-caspase inhibitor Z-VAD-fmk through pre-mitochondrial and MAPK-dependent pathways, Acta Med. Okayama, 59, 253
May, 2007, Caspase inhibition sensitizes inhibitor of NF-kappaB kinase beta-deficient fibroblasts to caspase-independent cell death via the generation of reactive oxygen species, J. Biol. Chem., 282, 16105, 10.1074/jbc.M611115200
Wilson, 2002, Death of HT29 adenocarcinoma cells induced by TNF family receptor activation is caspase-independent and displays features of both apoptosis and necrosis, Cell Death Differ., 9, 1321, 10.1038/sj.cdd.4401107
Chan, 2003, A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses, J. Biol. Chem., 278, 51613, 10.1074/jbc.M305633200
Vercammen, 1998, Dual signaling of the Fas receptor: initiation of both apoptotic and necrotic cell death pathways, J. Exp. Med., 188, 919, 10.1084/jem.188.5.919
Holler, 2000, Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule, Nat. Immunol., 1, 489, 10.1038/82732
Scheller, 2006, Caspase inhibition in apoptotic T cells triggers necrotic cell death depending on the cell type and the proapoptotic stimulus, J. Cell. Biochem., 97, 1350, 10.1002/jcb.20670
Yu, 2006, Autophagic programmed cell death by selective catalase degradation, Proc. Natl. Acad. Sci. U. S. A., 103, 4952, 10.1073/pnas.0511288103
Li, 2000, Induction of necrotic-like cell death by tumor necrosis factor alpha and caspase inhibitors: novel mechanism for killing virus-infected cells, J. Virol., 74, 7470, 10.1128/JVI.74.16.7470-7477.2000
Yu, 2004, Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8, Science, 304, 1500, 10.1126/science.1096645
Vandenabeele, 2006, Caspase inhibitors promote alternative cell death pathways, Sci. STKE, 2006, e44, 10.1126/stke.3582006pe44
Xu, 2006, Autophagy contributes to caspase-independent macrophage cell death, J. Biol. Chem., 281, 19179, 10.1074/jbc.M513377200
Ahn, 2001, Non-apoptotic signaling pathways activated by soluble Fas ligand in serum-starved human fibroblasts: mitogen-activated protein kinases and NF-kappaB-dependent gene expression, J. Biol. Chem., 276, 47100, 10.1074/jbc.M107385200
Scheller, 2002, Caspase inhibitors induce a switch from apoptotic to proinflammatory signaling in CD95-stimulated T lymphocytes, Eur. J. Immunol., 32, 2471, 10.1002/1521-4141(200209)32:9<2471::AID-IMMU2471>3.0.CO;2-E
Wajant, 2003, Non-apoptotic Fas signaling, Cytokine Growth Factor Rev., 14, 53, 10.1016/S1359-6101(02)00072-2
Choi, 2004, Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses, Brain Res. Brain Res. Rev., 44, 65, 10.1016/j.brainresrev.2003.08.007
Imamura, 2004, Fas ligand induces cell-autonomous NF-kappaB activation and interleukin-8 production by a mechanism distinct from that of tumor necrosis factor-alpha, J. Biol. Chem., 279, 46415, 10.1074/jbc.M403226200
Palao, 2006, Fas activation of a proinflammatory program in rheumatoid synoviocytes and its regulation by FLIP and caspase 8 signaling, Arthritis Rheum., 54, 1473, 10.1002/art.21768
Kondo, 1997, Essential roles of the Fas ligand in the development of hepatitis, Nat. Med., 3, 409, 10.1038/nm0497-409
Kuwano, 1999, Essential roles of the Fas–Fas ligand pathway in the development of pulmonary fibrosis, J. Clin. Invest, 104, 13, 10.1172/JCI5628
Rubinsztein, 2007, Potential therapeutic applications of autophagy, Nat. Rev. Drug Discovery, 6, 304, 10.1038/nrd2272
Shacka, 2006, Autophagy, bafilomycin and cell death: the “a-B-cs” of plecomacrolide-induced neuroprotection, Autophagy, 2, 228, 10.4161/auto.2703
Bubici, 2006, Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance, Oncogene, 25, 6731, 10.1038/sj.onc.1209936
Sakon, 2003, NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death, EMBO J., 22, 3898, 10.1093/emboj/cdg379
Kamata, 2005, Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases, Cell, 120, 649, 10.1016/j.cell.2004.12.041
Slee, 1996, Benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (Z-VAD.FMK) inhibits apoptosis by blocking the processing of CPP32, Biochem. J., 315, 21, 10.1042/bj3150021
Lamkanfi, 2007, Caspases in cell survival, proliferation and differentiation, Cell Death Differ., 14, 44, 10.1038/sj.cdd.4402047
Chen, 2002, TNF-R1 signaling: a beautiful pathway, Science, 296, 1634, 10.1126/science.1071924
Baud, 2001, Signal transduction by tumor necrosis factor and its relatives, Trends Cell Biol., 11, 372, 10.1016/S0962-8924(01)02064-5
Lin, 1999, Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis, Genes Dev., 13, 2514, 10.1101/gad.13.19.2514
Zheng, 2006, Competitive control of independent programs of tumor necrosis factor receptor-induced cell death by TRADD and RIP1, Mol. Cell. Biol., 26, 3505, 10.1128/MCB.26.9.3505-3513.2006
Hur, 2006, The death domain kinase RIP has an important role in DNA damage-induced, p53-independent cell death, J. Biol. Chem., 281, 25011, 10.1074/jbc.M605577200
Kim, 2007, TNF-induced activation of the Nox1 NADPH oxidase and its role in the induction of necrotic cell death, Mol. Cell, 26, 675, 10.1016/j.molcel.2007.04.021
Shen, 2006, JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species, Free Radic. Biol. Med., 40, 928, 10.1016/j.freeradbiomed.2005.10.056
Nadeau, 2007, Disulfide bond-mediated multimerization of Ask1 and its reduction by thioredoxin-1 regulate H2O2-induced c-Jun NH2-terminal kinase activation and apoptosis, Mol. Biol. Cell, 18, 3903, 10.1091/mbc.E07-05-0491
Ventura, 2004, JNK potentiates TNF-stimulated necrosis by increasing the production of cytotoxic reactive oxygen species, Genes Dev., 18, 2905, 10.1101/gad.1223004
Xu, 2006, Poly(ADP-ribose) polymerase-1 signaling to mitochondria in necrotic cell death requires RIP1/TRAF2-mediated JNK1 activation, J. Biol. Chem., 281, 8788, 10.1074/jbc.M508135200
Farley, 2006, Fas ligand elicits a caspase-independent proinflammatory response in human keratinocytes: implications for dermatitis, J. Invest. Dermatol., 126, 2438, 10.1038/sj.jid.5700477